In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

We recently published a list of Five Chinese Firms Dominate Friday’s Top 10 Gainers. In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA) stands against the other friday’s ...

While the details surrounding the new virus are still unfolding, the market's reaction reflects concern over the potential ...

Biotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...

As bad as it may look on the charts, Moderna’s (NASDAQ: MRNA) post-COVID let-down and market reset are over. The company ...

2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the fourth quarter and fiscal year 2024. "We have made progress in 2024 across our late-stage ...

In the preceding three months, 11 analysts have released ratings for Moderna (NASDAQ:MRNA), presenting a wide array of perspectives from bullish to bearish. The table below offers a condensed view ...

Moderna (NASDAQ:MRNA), the biotech company known for its Spikevax COVID-19 vaccine, released its fourth-quarter earnings on Feb. 14. The results revealed significant financial challenges as the ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...